https://www.pfizer.com/news/press-release/press-release-detail/pfizer_to_acquire_anacor
Old news, US5.2b
"...............In both of its Phase 3 pivotal studies, crisaborole achieved statistically significant results on all primary and secondary endpoints and in March 2016, the FDA accepted for review Anacor’s New Drug Application seeking approval of crisaborole for the potential treatment of mild-to-moderate atopic dermatitis in children and adults. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review is January 7, 2017. If approved, Pfizer believes peak year sales for crisaborole have the potential to reach or exceed $2.0 billion..........”
- Forums
- ASX - By Stock
- BOT
- BOT - Anything but charting
BOT - Anything but charting, page-333
Featured News
Add BOT (ASX) to my watchlist
(20min delay)
|
|||||
Last
32.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.5M |
Open | High | Low | Value | Volume |
32.5¢ | 32.5¢ | 31.5¢ | $1.940M | 6.061M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 470483 | 31.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
32.0¢ | 33000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 467608 | 0.315 |
27 | 806928 | 0.310 |
11 | 241226 | 0.305 |
31 | 495096 | 0.300 |
6 | 120637 | 0.295 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 33000 | 1 |
0.325 | 176270 | 4 |
0.330 | 80538 | 3 |
0.335 | 285000 | 3 |
0.340 | 834146 | 6 |
Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
Featured News
BOT (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online